The development of Panoptes´ clinical candidate PP-001 focuses on a new treatment for autoimmune uveitis, a disease which is one of the major causes of blindness. As a second indication, adenoviral conjunctivitis will be pursued, a disease for which to date, no treatment is available. Due to its unique mode of action, PP-001 has therapeutic potential for additional inflammatory and viral indications.
Panoptes has an experienced team of development experts with a proven track record of developing and commercializing innovative products. The team is developing a focused portfolio of high-performance small molecule products, with its lead clinical candidate PP-001 in preclinical development.
Panoptes’ aim is to generate future growth by achieving major development milestones and by entering into partnerships with leading pharmaceutical companies. We believe the combination of our technology and cost-efficient development strategy will help ensure a rapid and more predictable path to commercialization, and has the potential of making needed therapies available to more patients.